Circio Holding ASA (0RIS)
LSE
Closed
Aug 25, 2026
Day's Range
11.1052 wk Range
0.6020Overview - 0RIS - Circio Holding ASA
Key Statistics
Valuation
Enterprise Value
1.96B
EV / EBITDA
‪-47.93‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-157.47%‬
Ownership
Shares Outstanding
52.61M
Float
168.58M
Held by Insiders
‪32.42%‬
Held by Institutions
‪3.74%‬
Price stats
Beta
‪-1.16‬
50-Day Avg
‪24.22‬
200-Day Avg
‪24.22‬
Market Cap - 0RIS - Circio Holding ASA
Peers - 0RIS - Circio Holding ASA
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0RISLSECircio Holding ASA594.56MMarket Cap+94.64%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- 0MGBLSEGenmab A/S168.24BMarket Cap+25.25%52-week change30.65P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated141.26BMarket Cap+29.99%52-week change0.58P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.90.38BMarket Cap+29.97%52-week change0.12P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna, Inc.66.31BMarket Cap+81.03%52-week change55.34P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE51.17BMarket Cap+30.71%52-week change41.26P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA45.60BMarket Cap+11.01%52-week change127.93P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0RIS - Circio Holding ASA
About
Circio Holding ASA is a clinical-stage biotechnology company headquartered in Lysaker, Norway, specializing in the development of novel circular RNA (circRNA) therapeutics and immuno-oncology immunotherapies for treatment-resistant cancers and difficult-to-treat diseases. Formerly known as Targovax ASA until its…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
